Compare Bristol-Myers Squibb Co (BMY) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Marathon Petroleum Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.64 (market cap $129.94B), while Marathon Petroleum Corp trades at $342.22 (market cap $94.48B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | MPC | |
|---|---|---|
Market Cap | $129.94B | $94.48B |
Sector | Health | Energy |
52-Week High | $65.89 | $336.42 |
52-Week Low | $42.60 | $159.11 |
Enterprise Value | $163.92B | $121.00B |
Dividend Yield | 3.96% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Marathon Petroleum (MPC) trades at $342.47, up 6.91% with strong technical momentum and bullish analyst sentiment. The stock demonstrates robust fundamentals with Q2 2026 EPS of $17.73 beating estimates by 22.1%, supported by refining margin strength and disciplined operations. Valuation metrics remain attractive with P/E of 11.67 and EV/EBITDA of 6.87, while maintaining strong profitability with 47.9% ROE.
MPC presents a compelling investment case with projected revenue growth to $153.6B in 2026 and net profit margin expansion to 5.56%. Key risks include refining margin volatility and geopolitical impacts on energy markets. With 25 buy ratings and no sell recommendations, Wall Street consensus targets $332.70, though current price exceeds this level by 2.9%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
